Overview: The mass tort litigation over Actos (pioglitazone) is progressing, as the first federal trial is scheduled for 2014. The type 2 diabetes drug has sparked a number of lawsuits in recent years, mostly due its association with bladder cancer. Many of these lawsuits have been consolidated in the multidistrict litigation (MDL) known as the In re: Actos (Pioglitazone) Products Liability Litigation, which is being overseen by the Honorable Rebecca Doherty.
- The first Actos bladder cancer lawsuit it set to go to trial on November 3, 2014; the second trial is scheduled for July 8, 2015
- Many lawsuits alleging Actos caused bladder cancer have been filed into the MDL in the U.S. District Court for the Western District of Louisiana before the Honorable Rebecca Doherty
- There are as many as 10,000 Actos bladder cancer lawsuits in the US
Product: Actos (pioglitazone)
Manufacturer: Takeda Pharmaceutical/ Eli Lilly & Co.
Side Effects & Complications
- Bladder Cancer
- Heart Attacks
- Cardiovascular Problems
- Congestive Heart Failure
Court Order Sets First Trial for 2014
On July 13, the U.S. District Court for the Western District of Louisiana issued an order setting a timeline for the Actos MDL. The order set the first federal trial for November 3, 2014 and the second for July 8, 2015. According to the order, the potential trial cases must be selected by June 3, 2013.
The scheduling order means that the litigation is moving forward, despite the fact that the trial is more than two years away. Judge Doherty said that she set the dates after considering several factors, such as the number of lawsuits expected to be filed and the ones that have already been filed.
Actos Bladder Cancer Lawsuits
According to Bloomberg, Takeda may be facing over 10,000 lawsuits alleging Actos caused bladder cancer. Parker Waichman LLP, a national personal injury law firm, has filed a number of these suits on behalf of plaintiffs across the country. Last month, the firm filed a wrongful death lawsuit on behalf of the estates of two men who died of bladder cancer after taking Actos. At around the same time, Parker Waichman also filed a lawsuit on behalf of 10 bladder cancer patients alleging that Actos caused the cancer and subsequent complications.
There have been a number of research studies linking Actos to bladder cancer. In fact, use of the drug was suspended last June in France and Germany because of this association. In the US, the Food and Drug Administration (FDA) has been reviewing the results of an ongoing 10-year epidemiological study by Kaiser Permanente. Days after the drug was banned in Europe, the FDA updated the warning label on Actos and cautioned that use of the drug for one year was associated with a significant increased risk of bladder cancer.
Recently, a study published in the Canadian Medical Association Journal (CMAJ) found that patients taking Actos may be 22 percent more likely to develop bladder cancer.